New triple therapy aims to shrink high-risk rectal tumors before surgery
NCT ID NCT07527520
First seen Apr 18, 2026 · Last updated May 23, 2026 · Updated 10 times
Summary
This study tests whether a shorter course of radiation combined with chemotherapy and an immunotherapy drug (serplulimab) can help people with high-risk locally advanced rectal cancer achieve complete remission before surgery. About 165 adults with a specific type of rectal cancer (pMMR/MSS) will be randomly assigned to either the new combination or standard treatment. The goal is to see if the new approach leads to better tumor clearance and long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhongshan hosptial, Fudan University
Shanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.